Evoke Pharma, Inc.
EVOKNASDAQHealthcare
$11.00
+$11.00(+0.00%)
Market Cap$18946499
P/E Ratio—
52W High$11
52W Low$1.94
Evoke Pharma, Inc. (EVOK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EVOK · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $10.25M | $5.18M | $2.51M | $1.62M | $0.02M |
| Cost of Revenue | $0.36M | $0.20M | $0.37M | $0.33M | $0.09M |
| Gross Profit | $9.89M | $4.98M | $2.14M | $1.29M | ($0.06M) |
| Gross Margin %(computed) | 96.52% | 96.10% | 85.24% | 79.72% | -276.68% |
| Operating Expenses | |||||
| R&D Expenses | $0.02M | $0.18M | $0.30M | $0.59M | $6.55M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $15.10M | $12.41M | $9.92M | $9.44M | $12.98M |
| Operating Income | ($5.20M) | ($7.43M) | ($7.79M) | ($8.15M) | ($13.05M) |
| Operating Margin %(computed) | -50.77% | -143.44% | -310.37% | -503.79% | — |
| Interest Income | $0.35M | $0.14M | $0.06M | $0.01M | $0.01M |
| Interest Expense | $0.50M | $0.50M | $0.50M | $0.50M | $0.11M |
| Income Before Tax | ($5.35M) | ($7.79M) | ($8.22M) | ($8.54M) | ($13.15M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($5.35M) | ($7.79M) | ($8.22M) | ($8.54M) | ($13.15M) |
| Net Margin %(computed) | -52.22% | -150.41% | -327.83% | -527.66% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.81 | $-27.97 | $-31.16 | $-40.40 | $-74.91 |
| Wtd Avg Shares | 1.91M | 0.28M | 0.26M | 0.22M | 0.18M |
| EBITDA | $0.35M | ($7.15M) | ($7.72M) | ($8.04M) | ($13.04M) |
| EBITDA Margin %(computed) | 3.45% | -138.09% | -307.90% | -496.76% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Evoke Pharma, Inc. data
About Evoke Pharma, Inc. (EVOK) Income Statement
Evoke Pharma, Inc. (EVOK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, EVOK reported revenue of $0.01B, gross profit of $0.01B (gross margin 96.52%), and net income of ($0.01B) — a net profit margin of -52.22%.
Frequently asked questions
EVOK · 4 questionsEvoke Pharma, Inc. (EVOK) reported revenue of $0.01B for 2024, up 97.8% year-over-year.
EVOK revenueEVOK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09